The estimated Net Worth of Mc David Stilwell is at least $101 Thousand dollars as of 15 October 2021. Mr Stilwell owns over 3,507 units of Coherus Biosciences Inc stock worth over $42,043 and over the last 4 years he sold CHRS stock worth over $58,918.
Mr has made over 2 trades of the Coherus Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,507 units of CHRS stock worth $58,918 on 15 October 2021.
The largest trade he's ever made was buying 3,700 units of Coherus Biosciences Inc stock on 9 June 2021 worth over $49,654. On average, Mr trades about 721 units every 13 days since 2021. As of 15 October 2021 he still owns at least 31,611 units of Coherus Biosciences Inc stock.
You can see the complete history of Mr Stilwell stock trades at the bottom of the page.
McDavid Stilwell is the Chief Financial Officer at Coherus Biosciences Inc.
Mr Stilwell is 50, he's been the Chief Financial Officer of Coherus Biosciences Inc since . There are 14 older and 1 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
Mc's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle, and James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: